Neurocrine Biosciences Inc vs Stanley Black & Decker, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Stanley Black & Decker, Inc. trades at $87.62 (market cap $13.60B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays a 3.79% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SWK | |
|---|---|---|
Market Cap | $17.40B | $13.60B |
Sector | Health | — |
52-Week High | $180.55 | $94.12 |
52-Week Low | $123.10 | $62.12 |
Enterprise Value | $16.49B | $19.77B |
Dividend Yield | — | 3.79% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →